Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand.
Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May M, Blyth C, Ferguson J, Blackmore T, Riley TV, Athan E.
Int Med J 2016 [in press]
Antimicrobial surveillance of C. difficile in Australia.
Knight DR, Giglio S, Huntington PG, Korman TM, Kotsanas D, Moore CV, Paterson D, Prendergast L, Huber CA, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV.
J Antimicrob Chemother. 2015 Jul 28. pii: dkv220. [Epub ahead of print]
Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
Mackin KE, Elliott B, Kotsanas D, Howden BP, Carter GP, Korman TM, Riley TV, Rood JI, Jenkin GA, Lyras D.
Anaerobe. 2015 May 2. pii: S1075-9964(15)30017-2. doi: 10.1016/j.anaerobe.2015.05.001. [Epub ahead of print]
Diagnosis and Management of Clostridium difficile infection.
Semin Respir Crit Care Med. 2015 Feb;36(1):31-43. doi: 10.1055/s-0034-1398741. Epub 2015 Feb 2.
PMID: 25643269 [PubMed – in process]
Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain.
Lim SK, Stuart RL, Mackin K, Carter G, Kotsanas D, Francis M, Easton M, Dimovski K, Elliot B, Riley TV, Hogg G, Paul E, Korman TM, Seemann T, Stinear TP, Lyras D, Jenkin GA.
Clin Infect Dis. 2014 Apr 4. [Epub ahead of print]
PMID: 24704722 [PubMed – as supplied by publisher]
Johnson PD, Stuart RL.
Med J Aust. 2014 Mar 17;200(5):242-3. No abstract available.
PMID: 24641129 [PubMed – in process]
The Anti-Sigma Factor TcdC Modulates Hypervirulence in an Epidemic BI/NAP1/027 Clinical Isolate of Clostridium difficile.
Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, Spencer J, Buckley AM, Antunes A, Kotsanas D, Jenkin GA, Dupuy B, Rood JI, Lyras D.
PLoS Pathog. 2011 Oct;7(10):e1002317. Epub 2011 Oct 13.
PMID: 22022270 [PubMed – in process] Free PMC Article
Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice.
Ferguson JK, Cheng AC, Gilbert GL, Gottlieb T, Korman T, McGregor A, Richards M, Roberts S, Robson J, Van Gessel H, Riley TV.
Pathology. 2011 Aug;43(5):482-7. doi: 10.1097/PAT.0b013e328348c9b4.
PMID: 21716158 [PubMed – indexed for MEDLINE]
Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection.
Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, Roberts S, Korman TM, Riley TV.
Med J Aust. 2011 Apr 4;194(7):353-8.
PMID: 21470086 [PubMed – in process]
Clostridium difficile infection: a new threat on our doorstep.
Stuart RL, Marshall C.
Med J Aust. 2011 Apr 4;194(7):331-2.
PMID: 21470079 [PubMed – in process]
ASID/AICA position statement – Infection control guidelines for patients with Clostridium difficile infection in healthcare settings.
Stuart RL Marshall C, McLaws M, Boardman C, Russo PL, Harrington G, Ferguson JK.
Healthcare Infect 2011;16(1):33-39.
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001 AM2) (MODIFY I)
This is a randomized, double-blind, placebo-controlled, multicentre, Phase III study evaluating the efficacy, safety, and tolerability of monoclonal antibodies to C. difficile exotoxins. Participants receiving standard of care (SOC) therapy will be randomised equally into 1 of 4 treatment groups. On Day 1 participants will receive MK-3415 (toxin A only), MK-6072 (toxin B only), MK-3415A or placebo.
This study will investigate whether:
Proportion of participants with Clostridium difficile infection (CDI) recurrence [ Time Frame: 12 weeks ]
The aim of this study is to evaluate the efficacy of the candidate Clostridium difficile (C. difficile) vaccine to prevent primary symptomatic C. difficile infection (CDI) in subjects a risk for CDI where there is a substantial unmet medical need.
The study is designed as an event-driven group sequential protocol with 2 stages of enrollment, 3 interim analyses at defined clinical endpoints and a final analysis when number of clinical endpoints are reached.
In both Stage 1 and Stage 2, subjects will be randomly assigned to receive either the candidate vaccine or a placebo that will be administered in a 3-dose schedule. Stage 2 will be initiated after completing the second interim analysis of the Stage 1 cohort.
To assess the efficacy of the C. difficile vaccine in preventing the onset of symptomatic primary CDI confirmed by polymerase chain reaction (PCR) in adult subjects aged ≥ 50 years who are at risk for CDI and have received at least 1 injection.
To describe the immunogenicity to toxin A and toxin B in the subset of subjects at specific time points.
To describe the safety profile of all subjects who receive at least 1 injection.
Risk Stratum 1:
Risk Stratum 2: